

R1.126

~~24~~  
~~77~~

The pharmaceutical composition of claim ~~76~~<sup>75</sup> which influences the transport activity of a potassium transport channel comprising 2 P domains and 4 transmembrane segments.

Ad  
Cmld.  
R1.126

~~25~~  
~~78~~

The pharmaceutical composition of claim ~~77~~<sup>76</sup> which influences the transport activity of the potassium transport channel represented by SEQ ID. No. 2.

R1.126


~~26~~  
~~79~~

The pharmaceutical composition of claim ~~78~~<sup>77</sup> which is useful for the treatment of diseases selected from the group consisting of epilepsy, heart arrhythmias, vascular diseases, neurodegenerative diseases, ischemia or anoxia, endocrine diseases associated with anomalies of hormone secretion, and muscle diseases. -

#### REMARKS

This Preliminary Amendment is being filed to add claims directed to a screening method using the potassium channels "twik" and cells expressing such channels.

Respectfully submitted,



Gerard J. Weiser  
Reg. No. 19,763  
SCHNADER HARRISON SEGAL & LEWIS LLP  
Attorneys for Applicants